European journal of medicinal chemistry
A novel RANKL-targeted selenyl quinolinamide alleviates ovariectomy-induced bone loss through inhibiting ROS, MAPK and NF-κB signaling pathways.
Lele Yi, Yifan Ping, Xiaolong Ye, Shaoli Wang, Yao Wu, Lingling Zhou, Xiangrui Song, Haojin Chen, Bin Li, Yixin Mao, Yang Chen, Zhihao Yu, Weiwei Xue, Jing Wang, Shengbin Huang
Published: 202610.1016/j.ejmech.2025.118533
Abstract
The osteoclast is the only bone cell responsible for bone resorption, intracellular reactive oxygen species (ROS) are key signaling factors that regulate RANKL-induced osteoclast differentiation. Organoselenium compounds have been demonstrated with g…
Preview only. Read the full abstract at the source